Upper Airway Cough Syndrome Treatment Guidelines

Introduction to Treatment

The American College of Chest Physicians recommends that intranasal corticosteroids should be continued for 3 months after cough resolution when treating upper airway cough syndrome 1, 2, 3

Intranasal corticosteroids are not first-line therapy for upper airway cough syndrome—they should be initiated only after the cough disappears with initial combination therapy (antibiotic + first-generation antihistamine/decongestant + nasal decongestant for 5 days) 1, 2, 3
Once cough resolves, continue intranasal corticosteroids for 3 months to maintain symptom control and prevent recurrence 1, 2, 3

For allergic rhinitis-related upper airway cough syndrome, nasal corticosteroids are appropriate as first-line therapy alongside antihistamines and/or cromolyn when allergic rhinitis is the identified cause 4, 5
A 1-month trial is recommended for allergic rhinitis with postnasal drip 5
For chronic sinusitis-related upper airway cough syndrome, intranasal corticosteroids are part of the initial treatment regimen to decrease inflammation 3
Continue intranasal corticosteroids for 3 months after cough resolution as maintenance therapy for chronic sinusitis-related upper airway cough syndrome 1, 2, 3
For non-allergic rhinitis, intranasal corticosteroids may be used but are not as well-studied as first-generation antihistamine/decongestant combinations for this indication 4

Do not use intranasal corticosteroids as monotherapy initially for upper airway cough syndrome—they should follow or accompany combination therapy with antihistamine/decongestant 1, 2, 3
Do not discontinue intranasal corticosteroids prematurely—the 3-month continuation after cough resolution is critical for preventing recurrence 1, 2, 3
Do not confuse intranasal corticosteroids with nasal decongestants (like oxymetazoline), which are used short-term (5 days) during acute treatment, not for maintenance 3

The American College of Chest Physicians recommends starting with combination therapy, using a first-generation antihistamine/decongestant preparation alongside an intranasal corticosteroid, for allergic rhinitis with chronic cough 6
First-generation antihistamines are critical for treating the cough component due to their anticholinergic effect, unlike newer non-sedating antihistamines which have been shown to be ineffective for cough associated with upper airway cough syndrome 6
Intranasal corticosteroids can be started immediately alongside antihistamines for allergic rhinitis-related cough, unlike non-allergic upper airway cough syndrome where they are delayed 6
Nasal cromolyn can be used as an alternative first-line agent for allergic rhinitis-related upper airway cough syndrome 6
Ipratropium bromide nasal spray may be added if patients don't respond to the antihistamine/decongestant combination, though evidence is limited 6

The combination of intranasal fluticasone propionate plus intranasal azelastine provides superior symptom reduction compared to either agent alone, with a 40% relative improvement over monotherapy, for patients with moderate-to-severe allergic rhinitis and chronic cough 7
The 2017 Joint Task Force provides a weak recommendation for this combination as initial treatment for moderate-to-severe seasonal allergic rhinitis, due to cost and side effect considerations 7
Leukotriene receptor antagonists, such as montelukast 10 mg daily, are less effective than intranasal corticosteroids but may be considered for patients who cannot tolerate nasal sprays or have concurrent mild persistent asthma 7